Long-term efficacy of Gilenya reinforced by new analysis
Long-term efficacy of Gilenya reinforced by new analysis
Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya. The analysis evaluated the proportion of Gilenya patients with relapsing-remitting multiple sclerosis (RRMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years... Read More - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/